Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for First and Second Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Condition:   Pancreatic Cancer Interventions:   Biological: N-803;   Drug: Aldoxorubicin HCl;   Biological: PD-L1 t-haNK;   Drug: Nab-paclitaxel;   Drug: Gemcitabine;   Drug: Cyclophosphamide;   Drug: 5-Fluorouracil;   Drug: Leucovorin;   Procedure: SBRT;   Drug: Irinotecan liposome Sponsor:   ImmunityBio, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials